Monitoring of Risedronate by Biochemical Bone Markers in Clinical Practice
Narong Bunyaratavej MD*
Affiliation : *Department of Orthopaedic Surgery, Faculty of Medicine,Mahidol University
The study of trend of Risedronate 10 mg/day in menopausal women with a high level of resorptive bone marker(Betacrosslaps,CTx) by the following bone markers:Bone alkaline phosphatase(formation marker)total alkaline phosphatase(TAlP), NMID osteocalcin,undercarboxylated osteocalcin(UcOC)and procollagen type1 carboxyl propeptides(PICP). Risedronate does not suppress bone resorption deeply that enhances the bone recovers quickly after withdrawal. The level of undercarboxylated osteocalcin was in- creased after one year of treatment; it may be a sign of vitamin K2 deficiency. The bone alkaline phosphatase was decreased at the end of 12 months and Procollagen type 1 carboxyl propeptides(PICP) of twelfth month changed significantly compared to the sixth months of treatment(p=0.001) The once week 70 mg/week group also changed of CTx the same as daily dose group.
Keywords : Resorptive marker, Betacrosslaps,CTx,Bone alkaline phosphatase(B-AlP),Undercarboxylated osteocalcin,UcOC,NMID osteocalcin,Total alkaline phosphatase(T-AlP),Procollagen type 1 carboxyl propeptides(PICP)
